期刊
EPILEPTIC DISORDERS
卷 22, 期 -, 页码 S10-S15出版社
JOHN LIBBEY EUROTEXT LTD
DOI: 10.1684/epd.2020.1135
关键词
cannabidiol; epilepsy; mechanism; GPR55; TRPV1; adenosine
Highly purified cannabidiol (CBD) (approved as Epidiolex (R) in the United States and as EPIDYOLEX from the EU agency) has demonstrated efficacy with an acceptable safety profile in patients with Lennox-Gastaut or Dravet syndrome in four randomized controlled trials. While the mechanism of action of CBD underlying the reduction of seizures in humans is unknown, CBD possesses affinity for multiple targets, across a range of target classes, resulting in functional modulation of neuronal excitability, relevant to the pathophysiology of many disease types, including epilepsy. Here we present the pharmacological data supporting the role of three such targets, namely Transient receptor potential vanilloid-1 (TRPV1), the orphan G protein-coupled receptor-55 (GPR55) and the equilibrative nucleoside transporter 1 (ENT-1).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据